Centrifugal-Flow Left Ventricular Assist Device Noninferior

Share this content:
Centrifugal-Flow Left Ventricular Assist Device Noninferior
Centrifugal-Flow Left Ventricular Assist Device Noninferior

THURSDAY, Feb. 2, 2017 (HealthDay News) -- For patients with advanced heart failure, a newer-design centrifugal-flow left ventricular assist device (LVAD) is noninferior to an axial-flow LVAD, according to a study published in the Feb. 2 issue of the New England Journal of Medicine.

Joseph G. Rogers, M.D., from the Duke University School of Medicine in Durham, N.C., and colleagues conducted a multicenter trial involving 446 patients with advanced heart failure. Patients who were randomized to the study device (centrifugal-flow; 297 patients) or control device (axial-flow; 148 patients) were included as the intention-to-treat population. (One patient who had been assigned to the control device did not receive any device.)

The researchers found that the primary end point of survival at two years free from disabling stroke or device removal for malfunction or failure was achieved in 164 and 85 patients in the study and control groups, respectively. The primary end point analysis showed noninferiority of the study device versus the control device (estimated success rates: 55.4 and 59.1 percent, respectively; absolute difference, 3.7 percentage points; 95 percent upper confidence limit, 12.56 percentage points; P = 0.01 for noninferiority). Device malfunction or device failure requiring replacement occurred in more patients in the control group than the study group (16.2 versus 8.8 percent), while more patients in the study group had strokes (29.7 versus 12.1 percent).

"A small, intrapericardial, centrifugal-flow LVAD was found to be noninferior to an axial-flow LVAD with respect to survival free from disabling stroke or device removal for malfunction or failure," the authors write.

The study was funded by HeartWare, which makes the centrifugal-flow device.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Bavencio for Merkel Cell Carcinoma

FDA Approves Bavencio for Merkel Cell Carcinoma

Drug targets the PD-1/PD-L1 pathway; first sanctioned treatment in the United States

Heterogeneous Association for Alcohol, CVD Presentation

Heterogeneous Association for Alcohol, CVD Presentation

Non-drinking linked to increased risks of unstable angina, MI, heart failure, ischemic stroke, PAD, AAA

Mobile App Cuts In-Person Visits After Breast Reconstruction

Mobile App Cuts In-Person Visits After Breast Reconstruction

Number of visits down, increase in e-mails to doctors for ambulatory patients undergoing breast recon

is free, fast, and customized just for you!

Already a member?

Sign In Now »